Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of orelabrutinib versus placebo in non-active secondary progressive multiple sclerosis
2025-524322-18-00Phase 3Authorised
- Sponsor
- Zenas BioPharma
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Orelabrutinib with Placebo (2 arms). Primary endpoint: Time to onset of confirmed disability progression events confirmed over at least 24 weeks. Planned start Jul 2026; status: authorised.
02
Drugs
orelabrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2025-524322-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524322-18-00.